Developing a recombinanat vaccine for SARS

开发 SARS 重组疫苗

• 批准号: 6758299
• 负责人: Xuming Zhang
• 金额: $ 28.4万
• 依托单位: UNIV OF ARKANSAS FOR MED SCIS
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-01 至 2006-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6758299
• 关键词: SARS virus; complementary DNA; emerging infectious disease; live vaccine; microorganism growth; microorganism immunology; molecular cloning; polymerase chain reaction; recombinant proteins; severe acute respiratory syndrome; transfection /expression vector; vaccine development; virus DNA; virus genetics; virus protein

DESCRIPTION (provided by applicant): The current epidemic of the severe acute respiratory syndrome (SARS) is caused by a novel coronavirus, SARS-CoV. To date, the global confirmed SARS cases have reached >8,000 with L800 deaths in 30 countries. With an ease of transmission and severity of the disease, SARS poses a great threat to public health and causes significant economic loss. The long-term goal of this proposed research is to develop an efficacious vaccine for preventing future SARS epidemic. While various types of vaccines have been developed for different illnesses, current information obtained from studies on animal coronaviruses and their respective hosts suggests that the most promising vaccine for SARS would be a coronavirus-based live vaccine. However, the development of an attenuated, live SARS-CoV vaccine is a long-term approach with an unpredictable outcome. Previously, the P.I. has isolated a human enteric coronavirus (HECoV) associated with acute, mild diarrhea but with no other severe clinical symptoms. Based on the tenet of a common mucosal immune system, antigenic stimulation by oral immunization is usually very effective in inducing immunity to respiratory pathogens. Therefore, the P.I. proposes (i) to develop a recombinant human enteric coronavirus expressing the spike protein of the SARS-CoV as a vaccine for SARS, and (ii) to characterize the biological properties of the recombinant coronavirus. These studies can be accomplished within the proposed, short period of time and will provide crucial information about the utility of the recombinant coronavirus as an expression vector and as a candidate live vaccine for SARS. They will facilitate future clinical trials in animals and humans. Such a recombinant system will not only be important for the development of SARS vaccine but may provide potential avenues for the development of vaccines for other severe infectious diseases such as AIDS. It also provides a powerful molecular tool for studying pathogenesis and immunity of SARS-CoV. The practical impact of this research will be undoubtedly enormous. This research thus represents the exploratory nature of the R21 mechanism.

描述（由申请人提供）：当前流行的严重急性呼吸系统综合征（SARS）是由一种新型冠状病毒SARS- cov引起的。迄今为止，全球确诊的SARS病例已达到80000例，在30个国家有800人死亡。由于其易传播性和严重程度，SARS对公众健康构成巨大威胁，并造成重大经济损失。这项拟议研究的长期目标是开发一种有效的疫苗，以预防未来的SARS流行。虽然针对不同疾病已经开发了各种类型的疫苗，但目前从动物冠状病毒及其各自宿主的研究中获得的信息表明，最有希望的SARS疫苗将是基于冠状病毒的活疫苗。然而，研制减毒sars冠状病毒活疫苗是一种长期方法，其结果不可预测。此前，P.I.已经分离出一种与急性轻度腹泻相关的人类肠道冠状病毒（HECoV），但没有其他严重的临床症状。基于共同粘膜免疫系统的原则，口服免疫的抗原刺激通常在诱导呼吸道病原体免疫方面非常有效。因此，P.I.建议(i)开发一种表达SARS- cov刺突蛋白的重组人肠道冠状病毒作为SARS疫苗，以及（ii）表征重组冠状病毒的生物学特性。这些研究可以在拟议的短时间内完成，并将提供有关重组冠状病毒作为表达载体和SARS候选活疫苗的效用的重要信息。它们将促进未来在动物和人类身上的临床试验。这种重组系统不仅对SARS疫苗的开发很重要，而且可能为艾滋病等其他严重传染病疫苗的开发提供潜在的途径。这也为研究SARS-CoV的发病机制和免疫提供了强有力的分子工具。这项研究的实际影响无疑是巨大的。因此，本研究代表了R21机制的探索性。